PharmaCyte Biotech Inc. Company Profile
NASDAQ: PMCBHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
PharmaCyte Biotech at a glance
PharmaCyte Biotech Inc. (NASDAQ: PMCB) is a Biotechnology company in the Healthcare sector headquartered in Las Vegas, NV. PharmaCyte Biotech is led by Mr. Joshua N. Silverman and employs about 2 people. At a market capitalization of $4.3 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001157075, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does PharmaCyte Biotech do?
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Business description based on the company's public filings.
Company information
- Legal name
- PharmaCyte Biotech Inc.
- Ticker
- NASDAQ: PMCB
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Joshua N. Silverman
- Employees
- 2
- Headquarters
- 3960 Howard Hughes Parkway, Las Vegas, NV, United States
- Phone
- 917 595 2850
- Website
- pharmacyte.com
- Market cap
- $4.27M
- SEC CIK
- 0001157075
- Latest annual report
- 10-K · Jul 29, 2026
Companies similar to PharmaCyte Biotech
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ERNAErnexa Therapeutics Inc. | 2.49 | +4.18% | $4.06M | vs PMCB |
| PPCBPropanc Biopharma Inc. | 0.471 | -5.55% | $4.63M | vs PMCB |
| EOCNEocene Ltd. | 3.62 | +4.69% | $3.87M | vs PMCB |
| NCNANuCana plc ADR | 1.13 | -0.88% | $4.70M | vs PMCB |
| CLDICalidi Biotherapeutics Inc. | 1.04 | +2.97% | $3.82M | vs PMCB |
| PCSAProcessa Pharmaceuticals Inc. | 1.35 | -4.93% | $3.77M | vs PMCB |
| GRIGRI Bio Inc. | 1.68 | -9.19% | $3.67M | vs PMCB |
| JUNSJupiter Neurosciences Inc. | 2.77 | -2.46% | $3.65M | vs PMCB |